Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Denifanstat (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Ascletis

    • Most Recent Events

    • 02 Apr 2024 Planned End Date changed from 16 Sep 2023 to 31 Dec 2024.
    • 02 Apr 2024 Planned primary completion date changed from 16 Jul 2023 to 31 Dec 2024.
    • 25 Mar 2024 According to an Ascletis media release, in January 2024, the company announced the dosing of the first patient.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top